|
2024
|
Invention
|
Combination treatment regimens - smarca2 degrader with pd-1 inhibitors.
Disclosed are methods of... |
|
|
Invention
|
Combination treatment regimens - smarca2 degrader with gemcitabine. Disclosed are methods of trea... |
|
|
Invention
|
Combination treatment regimens - smarca2 degrader with taxane anticancer agent. Disclosed are met... |
|
|
Invention
|
Combination treatment regimens - smarca2 degrader with gemcitabine.
Disclosed are methods of tre... |
|
|
Invention
|
Combination treatment regimens - smarca2 degrader with pd-1 inhibitors. Disclosed are methods of ... |
|
|
Invention
|
Cdk inhibitors and their use as pharmaceuticals. The present invention provides methods of reduci... |
|
|
Invention
|
Brm targeting compounds and associated methods of use.
The disclosure is directed to compounds o... |
|
|
Invention
|
Mutant pi3k-alpha inhibitors and their use as pharmaceuticals.
The disclosure is directed to com... |
|
|
Invention
|
Mutant pi3k-alpha inhibitors and their use as pharmaceuticals. The disclosure is directed to comp... |
|
|
Invention
|
Treatment of recurrent high-grade glioma or uveal melanoma (um) using a brain-penetrant protein a... |
|
|
Invention
|
Cdk inhibitors and their use as pharmaceuticals.
The disclosure is directed to compounds of Form... |
|
|
Invention
|
Cdk inhibitors and their use as pharmaceuticals. The disclosure is directed to compounds of Formu... |
|
2023
|
Invention
|
Brm targeting compounds and associated methods of use. The present disclosure provides bifunction... |
|
|
Invention
|
Treatment of cancers using combinations of smarca2 degraders and kras targeting therapies. Method... |
|
|
Invention
|
Brm targeting compounds and associated methods of use. The disclosure is directed to compounds of... |
|
|
Invention
|
Kat6 targeting compounds.
The present disclosure provides bifunctional compounds comprising a ta... |
|
|
Invention
|
Kat6 targeting compounds with ubiquitin ligase binding moiety |
|
|
Invention
|
Kat6 targeting compounds with ubiquitin ligase binding moiety. The present disclosure provides bi... |
|
|
Invention
|
Processes for making prmt5 inhibitors |
|
|
Invention
|
Processes for making prmt5 inhibitors. The disclosure provides processes for preparing the compou... |
|
|
Invention
|
Brm targeting compounds and associated methods of use |
|
|
Invention
|
6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 pr... |
|
|
Invention
|
Cdk inhibitors and their use as pharmaceuticals.
The disclosure is directed to, in part, to CDK ... |
|
|
Invention
|
Thaizole-pyrimdiine cdk inhibitors and their use as pharmaceuticals. The disclosure is directed t... |
|
2022
|
Invention
|
Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (prm... |
|
|
Invention
|
Crystalline forms of a cdk9 inhibitor and uses thereof.
The present disclosure provides novel cr... |
|
|
Invention
|
Brm targeting compounds and associated methods of use.
The present disclosure provides bifunctio... |
|
|
Invention
|
Polymorphic compounds and uses thereof. The present invention provides freebase and salt forms us... |
|
2021
|
Invention
|
Heterocycle cdk inhibitors and their use thereof.
The disclosure is directed to, in part, to het... |
|
|
Invention
|
Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein.
The disc... |
|
|
Invention
|
Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein.
The ... |
|
2019
|
G/S
|
Research and development of drugs in the fields of oncology, hematology, autoimmune diseases, and... |
|
|
G/S
|
Research and development of drugs in the fields of oncology,
hematology, autoimmune diseases, an... |
